ESCRS - Better visual acuity with FLACS ;
ESCRS - Better visual acuity with FLACS ;

Better visual acuity with FLACS

Patient treated with FLACS had significantly better uncorrected visual acuity three hours after surgery than those treated with conventional phaco cataract surgery

Better visual acuity with FLACS
Howard Larkin
Howard Larkin
Published: Sunday, May 7, 2017
Karl Stonecipher MD
Patients treated with femtosecond laser-assisted cataract surgery (FLACS) had significantly better uncorrected visual acuity (UCVA) three hours after surgery than those treated with conventional phaco cataract surgery, Karl Stonecipher MD told the 2017 ASCRS•ASOA Symposium & Congress in Los Angeles, USA. Mean UCVA for 1,015 FLACS patients was 20/32 compared with 20/50 for 761 conventional phaco patients. “At three months they were comparable but my patients want to see instantly,” said Dr Stonecipher, of the University of North Carolina. The FLACS group also required significantly less ultrasound energy and time, he noted.
My patients want to see instantly
Patients with LOCS Grade II cataracts treated as part of the USFREE trial showed similar results, said Alfredo Tranjan Neto MD of Sao Paulo, Brazil. In a randomized interventional study 52 FLACS eyes achieved a mean best corrected visual acuity (BCVA) of 0.08 ±0.14 logMAR, or nearly 20/20, compared with 0.20 ±0.23, or about 20/32, for 52 conventional phaco eyes (P=0.00016). Dr Neto also reported significantly higher endothelial cell density in the FLACS group 30 days after surgery, with a mean 2,401.58 ±463.03 compared with 2,100.04 ±565.74 in the conventional phaco group (P=0.0051). At zero, phaco energy in the FLACS group was also significantly lower, while the volume of balanced salt solution used and surgical time were similar between the two groups. FLACS is potentially a safer procedure than conventional phaco cataract surgery and offers faster recovery time in patients with Grade II nuclei, Dr Neto concluded.                            
Latest Articles
From Lab to Life: Corneal Repair Goes Cellular

Long-awaited cellular therapies for corneal endothelial disease enter the clinic.

Read more...

Balancing Innovation and Safety

Ensuring access to advanced cell therapies amid regulatory overhaul.

Read more...

With Eyes on Its Future, ESCRS Celebrates Its Past

Winter Meeting offers opportunities to experiment with new concepts and formats.

Read more...

Best of ESCRS Winter Meeting 2024

Read more...

Following the New Generation

EDOF IOLs an option for eyes with mild comorbidities, showing potential in mini-monovision strategies.

Read more...

Refocus on Multifocals

Trifocal IOLs continue to improve as consensus grows regarding indications and contraindications.

Read more...

Common Myths in Presbyopia Correction

Patient education key to satisfaction with refractive IOLs.

Read more...

Reversible Multifocality

Two-lens combination offers low-risk spectacle independence for cataract patients and presbyopes.

Read more...

Managing a Cataract Surgery Refractive Miss

Weighing the pros and cons of options for intraocular intervention.

Read more...

Unleashing OCT’s Full Potential

Performance of newest tool for corneal evaluation meets or beats older standard technologies.

Read more...

;